Summit Therapeutics Inc Ordinary Shares SMMT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Summit Therapeutics' stock tumbles again as FDA recommends new trial for lung-cancer drug
Biotech's Monday Split: Two Trial Wins, One Trial Miss and an FDA Rejection
The FDA declined to approve one of biotech's most closely watched cancer drugs. The company's stock tumbled.
Summit Therapeutics Shares Sink After FDA Doesn't Approve Lung Cancer Treatment
Summit Therapeutics Provides Update Regarding Ivonescimab Biologics License Application
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2026
Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 Study Conducted by Akeso in China
Summit Therapeutics and Lunit Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development
Trading Information
- Previous Close Price
- $11.82
- Day Range
- $10.53–11.91
- 52-Week Range
- $10.53–29.23
- Bid/Ask
- $10.61 / $10.70
- Shares Outstanding
- 799.76M
- Market Cap
- $8.53B
- Volume/Avg
- 13M / 6M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 265
- Website
- https://www.smmttx.com
Valuation
Metric | SMMT |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 16.74 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
SMMT
Financial Strength
Metric | SMMT |
|---|---|
Quick Ratio | 5.71 |
Current Ratio | 5.99 |
Interest Coverage | — |
Quick Ratio
SMMT
Profitability
Metric | SMMT |
|---|---|
Return on Assets (Normalized) | −85.54% |
Return on Equity (Normalized) | −102.51% |
Return on Invested Capital (Normalized) | −99.19% |
Return on Assets
SMMT
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|ScHJ#B | LOCK|<x!?b | $136B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|NtzGRr$ | LOCK|@^s@ | $99B | |||
| Moderna Inc MRNA | LOCK|!^C$LY | LOCK|!m! | $87B | |||
| argenx SE ADR ARGX | LOCK|c&>YDl | LOCK|NZ | $61B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|KWg!$@ | LOCK|P&^ | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|^#W$$v^Q | LOCK|<d<wp | $31B | |||
| Incyte Corp INCY | LOCK|#<PF&hv | LOCK|cNV | $25B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|%FpDPm | LOCK|gBBqv | $21B | |||
| BioNTech SE ADR BNTX | LOCK|TZ#^%K | LOCK|$$D | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|Ymk<^! | LOCK|@XR | $15B |